Malaysia Biotech Head Calls For More Private Involvement
This article was originally published in PharmAsia News
Executive Summary
The head of Malaysia's biotechnology agency, BiotechCorp, called for more involvement by the private sector if the nation is to meet its goal of doubling the number of biotech firms by the end of this year. Of 63 Malaysian biotechs, 25 are in the health care business. BiotechCorp CEO Datuk Iskandar Mizal Mahmood said government funding needs to be complemented by private financing and capital markets if the goal of 120 biotech firms in Malaysia by the end of the year is to be met. After that, the government's master plan aims for a commercialization phase between 2011 and 2015. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.